Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials

• Main Authors: Lin Fan (Author), Yuanyuan Zhang (Author), Peter Maguire (Author), Dominic Muston (Author), Matthew Monberg (Author), Jagadeswara Rao Earla (Author), Adela Mihai (Author), Poonam Gulati (Author)
• Format: Book
• Published: Taylor & Francis Group, 2022-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background The economic impact of adverse events (AEs) for poly (ADP-ribose) polymerase inhibitors (PARPis) in ovarian or breast cancer has not been widely evaluated.Objective Compare PARPi-related AE management costs from a US payer perspective.Methods The frequency of treatment-related grade 3-4 A...